Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

With the introduction of immunotherapy, significant improvement has been made in the treatment of head and neck squamous cell carcinoma (HNSCC). However, only a small subset of patients with HNSCC benefit from immunotherapy. The current biomarker, a programmed cell death protein ligand 1 (PD-L1) exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jong Chul, Krishnakumar, Hari N., Saladi, Srinivas Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221564/
https://www.ncbi.nlm.nih.gov/pubmed/35735443
http://dx.doi.org/10.3390/curroncol29060334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221564/
https://www.ncbi.nlm.nih.gov/pubmed/35735443
http://dx.doi.org/10.3390/curroncol29060334

Ejemplares similares